On Friday, Moderna’s Covid-19 vaccination for children aged 12 to 17 was authorized by the European Medicines Agency (EMA).

According to the EU drug authority, the effects of the Spikevax vaccination were studied in a trial comprising 3,732 youngsters aged 12 to 17 years, which generated a comparable antibody response as found in young people aged 18 to 25 years.

According to the EMA, in comparison to four of 1,073 children given a placebo, none of the 2,163 children who received the Spikevax vaccination became infected with Covid-19.

The results enabled the Committee for Medicinal Products for Human Use (CHMP) to conclude that the efficacy of Moderna’s Covid-19 vaccination in 12- to 17-year-olds is comparable to that of adults.

LEAVE A REPLY

Please enter your comment!
Please enter your name here